oral glp-1 drugs in development Emerging Trends the of Receptor Agonists Upcoming wave of hormone-based therapies

These include a relative or absolute increase in glucagon secretion from alpha cells of the pancreas, elevated serum free fatty-acid concentrations, an impaired incretin effect (e.g., decreased secretion of glucagon-like peptide-1 [GLP-1]), enhanced renal reabsorption of glucose, and dysregulation of appetite control via decreased neurotransmitter response in the brain

& Cheng, X

A subset of CD8 T cells also express GLP-1R when exhausted

Bookmark it

Individual responses may vary, and this comparison is based on available research data, not a treatment recommendation

For example, Medicare covers MNT only for individuals with diagnoses of diabetes, chronic kidney disease, and 36 months post-kidney transplant, and for only 3 h during the first year of referral and 2 h annually thereafter [214]